调节或跳过:在卵巢癌中使用降级PARP抑制剂维持疗法,使用自适应疗法
Maximilian A R Strobl1, Alexandra L Martin2, Jeffrey West3
1Department of Integrated Mathematical Oncology, Moffitt Cancer Center, Tampa, FL, USA; Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
Cell systems
|May 21, 2024
概括
使用聚氨酸核糖酶聚合酶抑制剂 (PARPi) 剂量调整的自适应疗法,而不是跳过剂量,有效地减少了卵巢癌维持治疗中的药物使用,同时保持了治疗疗效.
科学领域:
- 在瘤学瘤学.
- 数学生物学 数学生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 卵巢癌的聚氨酸核糖聚合酶抑制剂 (PARPi) 维持疗法面临着毒性和耐药性的挑战.
- 根据瘤反应修改治疗的适应疗法提供了一个潜在的解决方案.
研究的目的:
- 调查卵巢癌中PARPi维持治疗的适应性治疗计划.
- 为了确定适应剂量或间歇性治疗是否在减少药物暴露和保持疗效方面更有效.
主要方法:
- 实验室时间缩短显微镜和逐步模型选择被用于开发和验证微分方程数学模型.
- 验证后的模型被用来模拟和比较各种适应性治疗策略.
主要成果:
- 数学建模表明,调整PARPi剂量比跳过治疗更有效,可以减少药物使用,同时保持治疗疗效.
- 这归因于延迟细胞杀死效果和剂量反应关系,较低剂量仍然部分有效.
结论:
- 适应性PARPi疗法,特别是通过剂量调整,可以减轻毒性,并可能延迟卵巢癌治疗中的耐药性.
- 这项研究为开发瘤学适应性治疗策略提供了一个框架.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515


